Biontech stock

biontech stock

Is biontech’s stock up 21% over the last month?

Messenger RNA technology leader BioNTech (NASDAQ: BNTX), has seen its stock rally by about 11% over the last week (five trading days) and remains up by almost 21% over the last month. This is well ahead of the S&P 500 which has returned about 2% over the last month.

What is the fundamental picture like for biontech?

So what’s the fundamental picture like for BioNTech? The Covid-19 vaccine has been very lucrative for the company as BioNTech shares gross profits on the vaccine with Pfizer on a 50:50 basis. Over Q1 2021, the company posted revenue of about $2. 5 billion, with Net Margins coming in at an incredible 55%.

Is biontech’s research pipeline more valuable than Moderna?

Although there are many moving parts relating to research pipelines, and it’s difficult to say which company’s pipeline could eventually be more valuable, BioNTech’s lower valuation multiple and its oncology-focused pipeline (cancer drugs are usually very lucrative) could give it more upside potential compared to Moderna. That said, there are ri...

Why are Moderna and biontech’s stocks rallying?

Messenger RNA technology leaders Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as investors see tremendous potential in leveraging mRNA technology beyond Covid, to fight a variety of diseases.

What is the fundamental picture like for biontech?

So what’s the fundamental picture like for BioNTech? The Covid-19 vaccine has been very lucrative for the company as BioNTech shares gross profits on the vaccine with Pfizer on a 50:50 basis. Over Q1 2021, the company posted revenue of about $2. 5 billion, with Net Margins coming in at an incredible 55%.

Is biontech’s research pipeline more valuable than Moderna?

Although there are many moving parts relating to research pipelines, and it’s difficult to say which company’s pipeline could eventually be more valuable, BioNTech’s lower valuation multiple and its oncology-focused pipeline (cancer drugs are usually very lucrative) could give it more upside potential compared to Moderna. That said, there are ri...

How do Moderna and biontech’s research and development pipelines compare?

Investors will need to look at Moderna and BioNTech pipelines more closely to value them for the long-term. BioNTech’s research pipeline is largely focused on cancer drugs (around 21 of its 27 candidates), while Moderna’s is more diverse, focusing on infectious diseases, vaccines, rare diseases, and cancer.

Is biontech a good stock to buy?

BioNTech: Better Stock To Play mRNA revolution Messenger RNA or mRNA technology has come of age, with the first two Covid-19 vaccines (Moderna and BioNTech/Pfizer PFE -4.1%) approved by Western regulators being based on the technology.

Why Moderna and biontech shares are up 75% and 150% year to date?

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as investors see tremendous potential in leveraging mRNA technology beyond Covid, to fight a variety of diseases.

What is the fundamental picture like for biontech?

So what’s the fundamental picture like for BioNTech? The Covid-19 vaccine has been very lucrative for the company as BioNTech shares gross profits on the vaccine with Pfizer on a 50:50 basis. Over Q1 2021, the company posted revenue of about $2. 5 billion, with Net Margins coming in at an incredible 55%.

Postagens relacionadas: